

**Stem Cell Reports, Volume 11**

**Supplemental Information**

**Recent Trends in Research with Human Pluripotent Stem Cells: Impact of Research and Use of Cell Lines in Experimental Research and Clinical Trials**

**Anke Guhr, Sabine Kobold, Stefanie Seltmann, Andrea E.M. Seiler Wulczyn, Andreas Kurtz, and Peter Löser**

## Supplementary tables

**Supplementary Table 1: Grouped citation frequencies of hESC research papers**

Country	Average citations per year (% of papers)			
	≤ 5	≤ 10	≤ 15	>15
Australia	86.8	5.3	5.3	2.6
Belgium	72.4	24.1	0.0	3.4
Canada	48.2	16.1	10.7	25
China	82.5	11,9	2.5	3.1
Finland	71.8	21.9	0.0	6.3
France	60.0	20.0	5.0	15.0
Germany	40.7	25.9	14.8	18.5
Japan	45.2	20.5	13.7	20.5
Iran	88.5	11.5	0.0	0.0
Israel	66.7	14.3	7.1	11.9
Korea	63.0	24.7	5.5	6.8
Netherlands	23.8	19.0	19.0	38.1
Singapore	55.9	27.1	6.8	10.2
Sweden	67.9	17.9	3.6	10.7
Spain	81.0	14.3	0.0	4.8
United Kingdom	44.7	33.0	7.8	14.6
United States	44.9	23.1	11.7	20.3
<b>Total</b>	56.0	20.9	8.4	14.7

**Supplementary Table 2: Grouped citation frequencies of hiPSC research papers**

Country	Average citations per year (% of papers)			
	≤ 5	≤ 10	≤ 15	>15
Australia	60.0	10.0	20.0	10.0
Canada	42.9	25.0	7.1	25.0
China	61.5	22.2	8.1	8.1
Finland	50	25	12.5	12.5
France	56.4	17.9	10.3	15.4
Germany	42.5	27.7	16.0	14.2
Iran	80.6	19.4	0.0	0.0
Israel	48.1	11.1	22.2	18.5
Italy	43.5	26.1	13.0	17.4
Japan	54.9	23.3	8.9	12.8
Korea	57.4	27.7	6.4	8.5
Netherlands	18.6	37.5	12.5	31.3
Singapore	56.4	25.6	7.7	10.3
Spain	62.5	18.8	12.5	6.3
Sweden	62.5	12.5	0.0	25.0
UK	33.3	33.3	11.1	22.2
United States	31.2	28.0	17.2	23.6
<b>Total</b>	53.2	22.6	10.3	14.0

Shown is the share of papers from selected countries within the indicated range of citations per year. Frequencies of citations per year of individual papers from the hESC field (table 1) and the hiPSC field (table 2) were assigned to 4 groups (up to 5, up to 10, up to 15 and more than 15 citations per paper and year). Shown is the percentage of papers from the respective country in each group.

**Supplementary Table 3: Origin of stem cell products used in hESC based clinical trials**

<b>hESC Line</b>	<b>Number of Clinical Trials</b>	<b>First Publication of Cell Line</b>
Cyt 49	4	2006
H1	2	1998
H9	2	1998
HADC102	1	2012
I6	1	2002
MA09	11	2006
Shef 1	1	2004
not specified	7	